
<SEC-DOCUMENT>0001102624-16-003263.txt : 20160811
<SEC-HEADER>0001102624-16-003263.hdr.sgml : 20160811
<ACCEPTANCE-DATETIME>20160811113139
ACCESSION NUMBER:
CONFORMED SUBMISSION TYPE:
PUBLIC DOCUMENT COUNT:
CONFORMED PERIOD OF REPORT:
FILED AS OF DATE:
DATE AS OF CHANGE:
6-K
3
20160811
0001102624-16-003263
20160811
20160811
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME:
CENTRAL INDEX KEY:
STANDARD INDUSTRIAL CLASSIFICATION: GOLD & SILVER ORES [1040]
IRS NUMBER:
STATE OF INCORPORATION:
FISCAL YEAR END:
REPLICEL LIFE SCIENCES INC.
0001205059
000000000
1231
A1
FILING VALUES:
FORM TYPE:
SEC ACT:
SEC FILE NUMBER: 000-50112
FILM NUMBER:
6-K
1934 Act
161823531
BUSINESS ADDRESS:
STREET 1:
CITY:
STATE:
ZIP:
BUSINESS PHONE:
MAIL ADDRESS:
STREET 1:
CITY:
STATE:
ZIP:
FORMER COMPANY:
SUITE 900 - 570 GRANVILLE STREET
VANCOUVER BC
A1
V6C 3P1
604-248-8693
SUITE 900 - 570 GRANVILLE STREET
VANCOUVER BC
A1
V6C 3P1
FORMER CONFORMED NAME: NEWCASTLE RESOURCES LTD.
DATE OF NAME CHANGE:
20081128
FORMER COMPANY:
FORMER CONFORMED NAME: PAN AMERICAN GOLD CORP
DATE OF NAME CHANGE:
20040521
FORMER COMPANY:
FORMER CONFORMED NAME: TRI LATERAL VENTURE CORP
DATE OF NAME CHANGE:
20021109
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>replicel6k.htm
<DESCRIPTION>REPLICEL LIFE SCIENCES 6-K
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Marketwired
    Document created using EDGARfilings PROfile 4.0.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" 
bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR:
#ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px 
solid; MARGIN-RIGHT: auto">
</div>
<div>&#160;</div>
<div><font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160; 
</font>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED 
STATES</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE 
COMMISSION</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C.&#160; 20549</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Form 6-K</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE 
ACT OF 1934</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">For the month of&#160;<font 
style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman';
FONT-SIZE: 10pt; FONT-WEIGHT: normal"><u>August 2016</u></font></div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Commission File Number <u>000-
</u><u>50112</u></div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>RepliCel Life 
Sciences Inc.</u></div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into 
English)</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Suite 2020 
&#8211; 401 West Georgia Street, Vancouver, British Columbia&#160; V6B 
5A1</u></div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">(Address of principal executive office)</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark whether the 
registrant files or will file annual reports under cover of Form 20-F or Form 
40-F.&#160; &#160;&#160; Form 20-F&#160;&#160;[X]&#160; Form 40-F&#160;&#160;
[&#160; ]</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Indicate by check mark if the 
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T 
Rule 101(b)(1) &#160;[&#160; ]</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 13.7pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: 
bold">Note:&#160; </font>Regulation S-T Rule 101(b)(1) only permits the 
submission in paper of a Form 6-K if submitted solely to provide an attached 
annual report to security holders.</div>
</div>
<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">&#160;</div>
<div style="MARGIN-TOP: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-BOTTOM: 
10pt; CLEAR: both; FONT-SIZE: 10pt" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; 
WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; 
COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: Calibri, sans-serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold"><u><br>
<font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">SUBMITTED 
HEREWITH</font></u><br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt"><a 
href="exh99_1.htm#Exhibit99.1">99.1&#160;</a>&#160;&#160;&#160;&#160;&#160;&#160
;&#160;&#160; RepliCel Life Sciences Announces Completion of the Final Injection
in its Tendon Repair Clinical Trial
<div id="DSPFPageFooter"></div>
<div style="LINE-HEIGHT: 12.55pt">&#160;</div>
</div>
<div style="MARGIN-TOP: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-BOTTOM: 
10pt; CLEAR: both; FONT-SIZE: 10pt" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; 
WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; 
COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt">Pursuant to the requirements of the 
Securities Exchange Act of 1934, the registrant has duly caused this report to 
be signed on its behalf by the undersigned, thereunto duly authorized.</div>
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt; FONT-
FAMILY: 'Times New Roman'; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RepliCel Life 
Sciences Inc.<br style="LINE-HEIGHT: 12.55pt">
</div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt"><u>/s/ Lee 
Buckler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&
#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#1
60;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160
;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">Lee Buckler, President &amp; CEO</div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New 
Roman'; FONT-SIZE: 10pt">Date:&#160; August 11, 2016</div>
<div style="LINE-HEIGHT: 12.55pt; MARGIN-TOP: 12pt"><br style="LINE-HEIGHT: 
12.55pt">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR:
#ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px 
solid; MARGIN-RIGHT: auto">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Marketwired
    Document created using EDGARfilings PROfile 4.0.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights 
reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" 
bgcolor="#ffffff" text="#000000">
<div>&#160;</div>
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR:
#ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px 
solid; MARGIN-RIGHT: auto">
</div>
<div style="TEXT-ALIGN: right; FONT-WEIGHT: bold"><a id="Exhibit99.1" 
name="Exhibit99.1"><!--Anchor--></a>Exhibit 99.1</div>
<div>
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #404040; FONT-SIZE: 14pt; FONT-WEIGHT: bold"><img 
src="image00001.jpg"></div>
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #595959; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NEWS RELEASE</div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #404040; FONT-SIZE: 14pt; FONT-WEIGHT: bold">&#160;</div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 14pt; FONT-WEIGHT: bold">RepliCel Life Sciences 
Announces Completion of the Final Injection in its <br>
 Tendon Repair Clinical Trial</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Initial Safety and Clinical 
Efficacy Data from the RCT-01 Trial is Expected to be Available for <br>
 Analysis in December</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">VANCOUVER, BC &#8211; August 
11, 2016 &#8211; RepliCel Life Sciences Inc. ("RepliCel" or the "Company") 
(OTCQB: REPCF)</font>&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(TSX.V: RP) (Frankfurt: P6P1)</font>,
a clinical stage regenerative medicine company focused on the development of 
autologous cell therapies,<font style="FONT-FAMILY: 'Times New Roman', Times, 
serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font>announced today that it 
has performed the final injection in its clinical trial of RCT-01 treating 
patients with chronic achilles tendinopathy. The last scheduled patient visit to
collect treatment follow-up data will be in late November.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">Clinical safety and 6-month efficacy data from 
the trial is expected to be un-blinded and made available for analysis and 
dissemination near year-end. Numerous measures of efficacy are being recorded in
the post-injection follow-up of the patients including function and pain scores 
as well as ultrasound imaging of the treated tendon.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">"This trial is a phase 1 safety trial designed 
to observe and measure certain signs of efficacy but not statistically powered 
for efficacy data.&#160; What we are looking for is a convincing signal, in at 
least some of the treated patients, that the product has clinically relevant 
outcomes in terms of restoration of function, reduction of pain, and/or 
regeneration of the tendon structure as measured by ultrasound imaging," stated 
RepliCel's Chief Medical Officer, Dr. Rolf Hoffmann.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">Data pertaining to the treatment's effects will
inform and guide the Company's product development and clinical trial strategy 
not only for achilles tendinopathy but also for numerous other tendon repair 
applications including the treatment of jumper's knee, golfer's elbow, tennis 
elbow, and rotator cuff.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">"We are confident the safety and preliminary 
efficacy data obtained by year-end will provide a signal of the product's 
potential to regenerate chronically injured tendons that have failed to respond 
to other treatments. This will allow our team to effectively plan the next-steps
for this asset both clinically and commercially," said R. Lee Buckler, 
RepliCel's President &amp; CEO.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">"Positive safety data and a signal of efficacy 
from this trial will support the Company in moving forward with a next-phase 
trial in 2017 and may also carry with it an opportunity to enter into a 
licensing and/or co-development agreement with a larger partner," Buckler 
concluded.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt"><u>RCT-01: Tendon Repair</u></div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">RCT-01 is a proprietary cell-therapy product 
comprised of non-bulbar dermal sheath (NBDS) cells which are type 1 collagen-
expressing fibroblasts derived from the hair follicle. The phase 1/2, single-
centre trial currently ongoing in Vancouver, British Columbia, is investigating 
the use of RCT-01 as a treatment for chronically injured ankle (Achilles) 
tendons otherwise called Achilles tendinopathy or tendinosis.</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; COLOR: #000000; CLEAR: both" 
id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; 
WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; 
CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
<div>
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">RepliCel Life Sciences Inc.</div>
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">News Release / 2</div>
</div>
<div style="COLOR: #000000">&#160;</div>
<div style="COLOR: #000000">&#160;</div>
<div style="COLOR: #000000"><br>
 &#160;</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif;
COLOR: #000000; FONT-SIZE: 10pt"><u>About RepliCel's NBDS Fibroblast 
Platform</u></div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-SIZE: 10pt">RepliCel's NBDS fibroblast platform has the 
potential to address numerous indications where impaired tissue healing has been
stalled due to a deficit of active fibroblast cells required for tissue 
remodeling and repair. RepliCel's proprietary&#160; NBDS fibroblast cells, 
isolated from healthy hair follicles, are a rich source of fibroblasts unique in
their high-level expression of the necessary proteins, such as Type I collagen, 
required to jump-start the stalled healing cycle. The company is developing a 
series of products from this platform that have the potential to address large 
commercial markets in the areas of musculoskeletal and skin-related conditions. 
To learn more about RepliCel's RCT-01 treatment for chronic tendinosis please 
</font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 
10pt"><u>watch our video</u></font><font style="FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-SIZE: 10pt">: </font><font style="FONT-FAMILY: 'Times New 
Roman', Times, serif; FONT-SIZE: 10pt"><u>www.youtube.com/watch?
t=23&amp;v=kaa0hiJyeV4</u></font></div>
<div style="TEXT-ALIGN: justify; COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>About RepliCel Life 
Sciences</u></div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">RepliCel is a regenerative medicine company 
focused on developing autologous cell therapies that address conditions caused 
by a deficit of healthy cells required for normal healing and function. The 
Company's product pipeline is comprised of two ongoing clinical trials (RCT-01: 
tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair 
restoration product under exclusive license by Shiseido Company for certain 
Asian countries.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-SIZE: 10pt">All product candidates are based on RepliCel's 
innovative technology, utilizing cell populations isolated from a patient's 
healthy hair follicles. The Company has also developed a proprietary injection 
device (RCI-02) optimized for the administration of its products and licensable 
for use with other dermatology applications. Please visit&#160;</font><font 
style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 
10pt"><u>www.replicel.com</u></font><font style="FONT-FAMILY: 'Times New Roman',
Times, serif; FONT-SIZE: 10pt"> for additional information.</font></div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">For more information, please contact:</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONTACT:</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">Lee Buckler, CEO and President</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', 
Times, serif; FONT-SIZE: 10pt">Telephone: 604-248-8693 / </font><font 
style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 
10pt"><u>lee@replicel.com</u></font></div>
<div style="COLOR: #000000"><br>
</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt">Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX Venture 
Exchange) accepts responsibility for the adequacy or accuracy of this 
release.</div>
<div style="COLOR: #000000"><br>
</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking 
Statements</div>
<div style="TEXT-ALIGN: justify; FONT-FAMILY: 'Times New Roman', Times, serif; 
COLOR: #000000; FONT-SIZE: 10pt; MARGIN-RIGHT: 9.35pt"><font style="FONT-STYLE: 
italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">This 
press release contains forward-looking information that involve various risks 
and uncertainties regarding future events. Such forward-looking information can 
include without limitation statements based on current expectations involving a 
number of risks and uncertainties and are not guarantees of future performance 
of RepliCel, such as statements regarding the Company's</font><font style="FONT-
STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> 
ability to move forward with a next phase trial in 2017and </font><font 
style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">enter into
a licensing and/or co-development agreement with a larger partner</font><font 
style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-
SIZE: 10pt">. Such forward-looking statements and information are based on 
current expectations involving a number of risks and uncertainties and are not 
guarantees of future performance of RepliCel. There are numerous risks and 
uncertainties that could cause actual results and RepliCel's plans and 
objectives to differ materially from those expressed in the forward-looking 
information, including: failure to obtain CE mark clearance or necessary 
regulatory approvals; delays enrolling clinical trial participants; negative 
results from the Company's trials; the effects of government regulation on the 
Company's business; risks associated with the Company's ability to obtain and 
protect rights to its intellectual property; risks and uncertainties associated 
with the Company's ability to raise additional capital; and other factors beyond
the Company's control. Actual results and future events could differ materially 
from those anticipated in such information. These and all subsequent written and
oral forward-looking information are based on estimates and opinions of 
management on the dates they are made and are expressly qualified in their 
entirety by this notice. Except as required by law, RepliCel does not intend to 
update these forward-looking statements.</font></div>
<div><br>
</div>
<div><br>
</div>
<div><br>
</div>
<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #404040; FONT-SIZE: 10pt">##</div>
<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #404040; FONT-SIZE: 10pt">&#160;</div>
<div style="TEXT-ALIGN: center; FONT-STYLE: italic; FONT-FAMILY: 'Times New 
Roman', Times, serif; COLOR: #404040; FONT-SIZE: 10pt">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR:
#ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px 
solid; MARGIN-RIGHT: auto">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !8 *\# 2(  A$! Q$!_\0
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M987S3"XU&3RX D98$Y Y/;EA4OB/78=!MH9[BUO+A)95A'V:,.0S$!0>1U)
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end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>